STRENSIQ 28 mg/.7mL (Asfotase Alfa SOLUTION) 28 mg/.7mL

STRENSIQ 28 mg/.7mL is a subcutaneous solution containing asfotase alfa, used for managing hypophosphatasia. This enzyme replacement therapy is designed to address bone mineralization issues. Learn more about its uses and effects.

Strength

28 mg/.7mL

Pack Size

12 VIAL in 1 CARTON (25682-013-12) / .7 mL in 1 VIAL (25682-013-01)

Manufacturer / TM Owner

Alexion Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

STRENSIQ 28 mg/.7mL is primarily used for the treatment of hypophosphatasia, a rare genetic disorder that affects bone and tooth development. This solution helps in improving bone mineralization and reducing the risk of bone-related complications. Patients often seek information on 'what is STRENSIQ used for' and how it can support bone health.

Side Effects

Common effects of STRENSIQ 28 mg/.7mL may include improvements in bone density and reduction in bone pain. Some users may experience injection site reactions, such as redness or swelling. It is important to monitor for any adverse reactions and consult a healthcare provider if concerns arise.

Precautions & Warnings

STRENSIQ 28 mg/.7mL should be handled with care, ensuring proper storage and administration techniques. It is crucial to follow the prescribed guidelines for subcutaneous injection to minimize the risk of complications. Always consult a healthcare professional for personalized advice.

Avoid Interactions

STRENSIQ 28 mg/.7mL may interact with other medications, particularly those that affect the immune system or bone metabolism. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also influence the effectiveness of this treatment.

Frequently Asked Questions

STRENSIQ is used to manage hypophosphatasia, a genetic disorder affecting bone and tooth development.

STRENSIQ is administered subcutaneously, typically via injection.

Common side effects may include injection site reactions, such as redness or swelling.

It is important to consult a healthcare provider to check for potential interactions with other medications.

STRENSIQ should be stored according to the manufacturer's guidelines to maintain its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.